title: Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
abstract: Immunoglobulin replacement therapy has been standard treatment in patients with primary immunodeficiency diseases for the past 3 decades. The goal of therapy is to reduce serious bacterial infections in individuals with antibody function defects. Approximately one-third of patients receiving intravenous immunoglobulin treatment experience adverse reactions. Recent advances in manufacturing processes have resulted in products that are safer and better tolerated. Self-infusion by the subcutaneous route has become popular and resulted in better quality of life. This review summarizes the use of immunoglobulin therapy in primary immunodeficiency diseases including its properties, dosing, adverse effects, and different routes of administration.
authors.affiliation: Division of Allergy and Immunology, Department of Pediatrics, University of South Florida, 140 7th Avenue South, CRI 4008, Saint Petersburg, FL 33701, USA. Electronic address: psriaroo@health.usf.edu.
authors.forename: Panida
authors.initials: P
authors.lastname: Sriaroon
authors.affiliation: Division of Allergy and Immunology, Department of Pediatrics, University of South Florida, 140 7th Avenue South, CRI 4008, Saint Petersburg, FL 33701, USA.
authors.forename: Mark
authors.initials: M
authors.lastname: Ballow
mesh_terms: D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects / Q000379:methods; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use; D007136:Immunoglobulins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000188:drug therapy*; D007279:Injections, Subcutaneous; D008991:Monitoring, Physiologic; D016896:Treatment Outcome
chemical_list: D007074:Immunoglobulin G; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous
keywords: IVIG; Immunoglobulin replacement therapy; Intravenous immunoglobulin; Primary immunodeficiency; SCIG; Subcutaneous immunoglobulin